{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:52:40Z","timestamp":1790887960070,"version":"4.1.0"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/bor.0b013e328358ac72","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T10:37:11Z","timestamp":1346927831000},"page":"635-641","source":"Crossref","is-referenced-by-count":52,"title":["Therapeutic advances in myositis"],"prefix":"10.1097","volume":"24","author":[{"given":"Rohit","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-4615-4857-7_54","article-title":"The effect of methylprednisolone pulse therapy in polymyositisdermatomyositis.","volume":"455","author":"Bolosiu","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"key":"R3-9-20210128","first-page":"S53","article-title":"Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy.","volume":"199","author":"Miller","year":"2002","journal-title":"J Neurol Sci"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis.","volume":"29","author":"Vencovsky","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"R5-9-20210128","first-page":"665","article-title":"Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment: best practice research.","volume":"23","author":"Wedderburn","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/art.30475","article-title":"Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study.","volume":"63","author":"Hasija","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Childrens Arthritis and Rheumatology Research Alliance Consensus Conference.","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar3704","article-title":"Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine.","volume":"14","author":"Schiopu","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","article-title":"Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens.","volume":"41","author":"Villalba","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-011-1840-0","article-title":"Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.","volume":"30","author":"Yu","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08916930500124023","article-title":"Polymyositisdermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.","volume":"38","author":"Takada","year":"2005","journal-title":"Autoimmunity"},{"key":"R12-9-20210128","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin A and 2-h postdose blood concentration monitoring improves the prognosis of acutesubacute interstitial pneumonia in dermatomyositis.","volume":"35","author":"Kotani","year":"2008","journal-title":"J Rheumatol"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.autrev.2011.09.007","article-title":"Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature.","volume":"11","author":"Ingegnoli","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","article-title":"Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acutesubacute interstitial pneumonia.","volume":"30","author":"Kotani","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R16-9-20210128","first-page":"188","article-title":"The effects of FK506 on refractory inflammatory myopathies.","volume":"111","author":"Mitsui","year":"2011","journal-title":"Acta neurologica Belgica"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10067-009-1358-x","article-title":"Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine.","volume":"29","author":"Ando","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","article-title":"Cyclosporin A and intravenous immunoglobulin treatment in polymyositisdermatomyositis.","volume":"61","author":"Danieli","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.","volume":"121","author":"Manlhiot","year":"2008","journal-title":"Pediatrics"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis.","volume":"70","author":"Lam","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R23-9-20210128","first-page":"397","article-title":"The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study.","volume":"30","author":"Kampylafka","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositisdermatomyositis.","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis.","volume":"140","author":"Diot","year":"2011","journal-title":"Chest"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin.","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R29-9-20210128","first-page":"1245","article-title":"Mycophenolate mofetil in dermatomyositis: is it safe N","volume":"66","author":"Rowin","year":"2006","journal-title":"eurology"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","article-title":"Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy.","volume":"44","author":"Majithia","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","article-title":"Mycophenolate mofetil treatment in resistant myositis.","volume":"46","author":"Pisoni","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis.","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis.","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis.","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects.","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/acr.20269","article-title":"Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.","volume":"62","author":"Rouster-Stevens","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00296-010-1653-5","article-title":"Mycophenolate mofetil in juvenile dermatomyositis: a case series.","volume":"32","author":"Dagher","year":"2012","journal-title":"Rheumatol Int"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.jaad.2004.03.020","article-title":"Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate.","volume":"51","author":"Waldman","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R40-9-20210128","first-page":"1009","article-title":"Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.","volume":"27","author":"Rios Fernandez","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: a case series.","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/acr.20378","article-title":"Rituximab therapy for myopathy associated withanti-signal recognition particle antibodies: a case series. Comment on the article by Valiyil et al.","volume":"63","author":"Deligny","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/rheumatology\/kep027","article-title":"Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion.","volume":"48","author":"Whelan","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","article-title":"Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).","volume":"16","author":"Arlet","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies.","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis.","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"R47-9-20210128","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study.","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R48-9-20210128","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.22856","article-title":"Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.","volume":"56","author":"Cooper","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R49-9-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1525-1470.2011.01501.x","article-title":"Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.","volume":"28","author":"Chiu","year":"2011","journal-title":"Pediatric Dermatol"},{"key":"R50-9-20210128","first-page":"3844","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM): the RIM study.","volume":"62","author":"Oddis","year":"2010","journal-title":"Arthritis Res"},{"key":"R51-9-20210128","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semarthrit.2006.07.003","article-title":"Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications.","volume":"36","author":"Efthimiou","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"R52-9-20210128","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R53-9-20210128","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R54-9-20210128","first-page":"S293","article-title":"A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis.","volume":"58","author":"Coyle","year":"2008","journal-title":"Arthritis Res"},{"key":"R55-9-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","article-title":"Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.","volume":"59","author":"Hengstman","year":"2008","journal-title":"Eur Neurol"},{"key":"R56-9-20210128","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series.","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"R57-9-20210128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis.","volume":"70","year":"2011","journal-title":"Ann Neurol"},{"key":"R58-9-20210128","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","article-title":"Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature.","volume":"29","author":"Ishikawa","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R59-9-20210128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor inhibitor-associated dermatomyositis.","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"key":"R60-9-20210128","first-page":"192","article-title":"Antitumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis.","volume":"39","author":"Riolo","year":"2012","journal-title":"J Rheumatol"},{"key":"R61-9-20210128","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3899\/jrheum.091413","article-title":"Dermatomyositis during adalimumab therapy for rheumatoid arthritis.","volume":"37","author":"Brunasso","year":"2010","journal-title":"J Rheumatol"},{"key":"R62-9-20210128","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","article-title":"IL-6BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.","volume":"141","author":"Okada","year":"1988","journal-title":"J Immunol"},{"key":"R63-9-20210128","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.1780371206","article-title":"Elevated serum levels of interleukin-1 receptor antagonist in polymyositisdermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.","volume":"37","author":"Gabay","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R64-9-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R65-9-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2990.1998.00092.x","article-title":"Local expression of cytokines in idiopathic inflammatory myopathies.","volume":"24","author":"Lepidi","year":"1998","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R66-9-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.03.026","article-title":"IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis.","volume":"176","author":"Scuderi","year":"2006","journal-title":"J Neuroimmunol"},{"key":"R67-9-20210128","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","article-title":"Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A.","volume":"60","author":"Okiyama","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R68-9-20210128","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis.","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"key":"R69-9-20210128","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1100\/tsw.2010.173","article-title":"The melanocortin system in control of inflammation.","volume":"10","author":"Catania","year":"2010","journal-title":"ScientificWorldJournal"},{"key":"R70-9-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.56.1.1","article-title":"Targeting melanocortin receptors as a novel strategy to control inflammation.","volume":"56","author":"Catania","year":"2004","journal-title":"Pharmacol Rev"},{"key":"R71-9-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study.","volume":"97","author":"Baram","year":"1996","journal-title":"Pediatrics"},{"key":"R72-9-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/DDDT.S17521","article-title":"Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.","volume":"5","author":"Bomback","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"R73-9-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/DDDT.S19331","article-title":"Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial.","volume":"5","author":"Simsarian","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"R74-9-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/DDDT.S33110","article-title":"Treating refractory dermatomyosits or polymyositis with adrenocorticotropic hormone gel: a retrospective case series.","volume":"6","author":"Levine","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"R75-9-20210128","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"key":"R76-9-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.autrev.2011.04.028","article-title":"Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature.","volume":"10","author":"Pons-Estel","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R77-9-20210128","first-page":"S489","article-title":"A pilot study of eculizumab in patients with dermatomyositis.","volume":"46","author":"Kazuki","year":"2002","journal-title":"Arthritis Res"},{"key":"R78-9-20210128","first-page":"2080","article-title":"Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.","volume":"35","author":"Thompson","year":"2008","journal-title":"J Rheumatol"},{"key":"R79-9-20210128","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"R80-9-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis.","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"R81-9-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis.","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e328358ac72","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T23:53:47Z","timestamp":1714348427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201211000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328358ac72","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}